Marc Bos

4.0k total citations
12 papers, 162 citations indexed

About

Marc Bos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Marc Bos has authored 12 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Marc Bos's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (3 papers) and RNA modifications and cancer (2 papers). Marc Bos is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (3 papers) and RNA modifications and cancer (2 papers). Marc Bos collaborates with scholars based in Germany. Marc Bos's co-authors include Hans‐Ulrich Schildhaus, Reinhard Büttner, Anne M. Schultheis, Jürgen Wolf, Elke Binot, Katja Schmitz, Masyar Gardizi, Reinhard Buettner, Matthias Scheffler and Lukas C. Heukamp and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Modern Pathology.

In The Last Decade

Marc Bos

11 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Bos Germany 5 90 84 82 43 22 12 162
Gongyan Chen China 7 85 0.9× 90 1.1× 76 0.9× 36 0.8× 10 0.5× 13 163
Haitao Ma China 8 52 0.6× 63 0.8× 71 0.9× 35 0.8× 10 0.5× 22 150
Alejandro Falcón Spain 6 44 0.5× 89 1.1× 54 0.7× 24 0.6× 22 1.0× 29 135
Wenjun Yu China 9 97 1.1× 79 0.9× 151 1.8× 98 2.3× 11 0.5× 18 268
Katrin Madjar Germany 7 52 0.6× 77 0.9× 97 1.2× 41 1.0× 25 1.1× 14 187
Avinash Viswanathan United States 6 121 1.3× 77 0.9× 114 1.4× 33 0.8× 8 0.4× 9 209
James F. Catroppo United States 6 125 1.4× 66 0.8× 62 0.8× 46 1.1× 7 0.3× 6 223
Cody Weimholt United States 7 67 0.7× 63 0.8× 91 1.1× 33 0.8× 10 0.5× 15 168
Tadashi Manabe Japan 6 95 1.1× 101 1.2× 90 1.1× 26 0.6× 6 0.3× 12 216
Masyar Gardizi Germany 5 85 0.9× 65 0.8× 58 0.7× 38 0.9× 4 0.2× 9 124

Countries citing papers authored by Marc Bos

Since Specialization
Citations

This map shows the geographic impact of Marc Bos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Bos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Bos more than expected).

Fields of papers citing papers by Marc Bos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Bos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Bos. The network helps show where Marc Bos may publish in the future.

Co-authorship network of co-authors of Marc Bos

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Bos. A scholar is included among the top collaborators of Marc Bos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Bos. Marc Bos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
3.
Nogová, Lucia, Masyar Gardizi, Marc Bos, et al.. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.. Journal of Clinical Oncology. 32(15_suppl). 8109–8109. 2 indexed citations
4.
Scheffler, Matthias, Masyar Gardizi, Marc Bos, et al.. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.. Journal of Clinical Oncology. 32(15_suppl). TPS2645–TPS2645. 1 indexed citations
5.
Schultheis, Anne M., Marc Bos, Katja Schmitz, et al.. (2013). Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Modern Pathology. 27(2). 214–221. 76 indexed citations
6.
Bos, Marc, Masyar Gardizi, Hans‐Ulrich Schildhaus, et al.. (2013). Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer. 81(1). 142–143. 31 indexed citations
7.
Nogová, Lucia, Masyar Gardizi, Matthias Scheffler, et al.. (2013). SORAVE: Sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC—A phase I study.. Journal of Clinical Oncology. 31(15_suppl). 8112–8112. 1 indexed citations
8.
Bos, Marc, Masyar Gardizi, Hans‐Ulrich Schildhaus, Reinhard Buettner, & Juergen Wolf. (2013). Activated RET and ROS: two new driver mutations in lung adenocarcinoma.. PubMed. 2(2). 112–21. 14 indexed citations
9.
Scheffler, Matthias, Lucia Nogová, Masyar Gardizi, et al.. (2012). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.. Journal of Clinical Oncology. 30(15_suppl). TPS3115–TPS3115. 1 indexed citations
10.
Zander, Thomas, Lukas C. Heukamp, Marc Bos, et al.. (2012). Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.. Journal of Clinical Oncology. 30(15_suppl). CRA10529–CRA10529. 7 indexed citations
11.
Zander, Thomas, Lukas C. Heukamp, Marc Bos, et al.. (2012). Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.. Journal of Clinical Oncology. 30(18_suppl). CRA10529–CRA10529. 4 indexed citations
12.
Bosschere, H. De, Marc Bos, R. Ducatelle, Sofie Bhatti, & Luc Van Ham. (2002). Spongiform degeneration of the white matter in the central nervous system of australian cattle dog littermates. Vlaams Diergeneeskundig Tijdschrift. 71(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gongyan Chen Breakdown of academic impact, for papers by Haitao Ma Breakdown of academic impact, for papers by Alejandro Falcón Breakdown of academic impact, for papers by Wenjun Yu Breakdown of academic impact, for papers by Katrin Madjar Breakdown of academic impact, for papers by Avinash Viswanathan Breakdown of academic impact, for papers by James F. Catroppo Breakdown of academic impact, for papers by Cody Weimholt Breakdown of academic impact, for papers by Tadashi Manabe Breakdown of academic impact, for papers by Masyar Gardizi
Rankless by CCL
2026